<DOC>
	<DOCNO>NCT00757029</DOCNO>
	<brief_summary>The noradrenergic system play know role attentional system suspect causal role attention deficit/hyperactivity disorder ( ADHD ) .Methylphenidate also suspect inhibitor norepinephrine transporter ( SLC6A2 ) . The investigator hypothesis norepinephrine transporter polymorphism associate response adverse effect OROS-methylphenidate treatment ADHD .</brief_summary>
	<brief_title>Pharmacogenetic Study Methylphenidate Attention Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>ADHD Physically healthy Neurological illness Concurrent additional psychiatric treatment &lt; IQ 70 Psychotic disorder Major mood disorder need psychiatric medication Significant suicidal ideation Pervasive developmental disorder</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>ADHD ,</keyword>
	<keyword>norepinephrine transporter</keyword>
	<keyword>pharmacogenetics</keyword>
</DOC>